Matthew Sykes
Stock Analyst at Goldman Sachs
(2.25)
# 630
Out of 4,829 analysts
203
Total ratings
35.38%
Success rate
-2.98%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $9.60 | -32.29% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $40.45 | +11.25% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $4.04 | +98.02% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $32.97 | +45.59% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $13.44 | +26.49% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $142.50 | +12.28% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $8.40 | +19.05% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $97.91 | +27.67% | 2 | Apr 29, 2025 | |
| AVTR Avantor | Downgrades: Neutral | $23 → $14 | $12.95 | +8.15% | 6 | Apr 29, 2025 | |
| DHR Danaher | Maintains: Buy | $260 → $240 | $200.02 | +19.99% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $16.02 | +62.30% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $145.59 | +16.77% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $22 → $11 | $5.50 | +100.00% | 3 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $41.53 | +34.86% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $60.08 | +33.16% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $1.17 | +28.76% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $155.70 | +22.03% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $0.72 | +142.28% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $2.12 | +100.47% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $30.64 | +20.76% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $53.58 | +21.31% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $156.36 | +59.89% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $5.82 | +312.37% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,169.71 | +11.14% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $8.39 | +43.11% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $431.08 | +48.46% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $10 | $3.15 | +217.97% | 8 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $115.29 | +25.77% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $42.60 | - | 5 | Dec 7, 2023 |
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $9.60
Upside: -32.29%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $40.45
Upside: +11.25%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $4.04
Upside: +98.02%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $32.97
Upside: +45.59%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $13.44
Upside: +26.49%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $142.50
Upside: +12.28%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $8.40
Upside: +19.05%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $97.91
Upside: +27.67%
Avantor
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $12.95
Upside: +8.15%
Danaher
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $200.02
Upside: +19.99%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $16.02
Upside: +62.30%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $145.59
Upside: +16.77%
Mar 4, 2025
Maintains: Neutral
Price Target: $22 → $11
Current: $5.50
Upside: +100.00%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $41.53
Upside: +34.86%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $60.08
Upside: +33.16%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.17
Upside: +28.76%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $155.70
Upside: +22.03%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $0.72
Upside: +142.28%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $2.12
Upside: +100.47%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $30.64
Upside: +20.76%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $53.58
Upside: +21.31%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $156.36
Upside: +59.89%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $5.82
Upside: +312.37%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,169.71
Upside: +11.14%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $8.39
Upside: +43.11%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $431.08
Upside: +48.46%
Feb 29, 2024
Maintains: Buy
Price Target: $9 → $10
Current: $3.15
Upside: +217.97%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $115.29
Upside: +25.77%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $42.60
Upside: -